Thank you to all who joined us on Wednesday, January 21st! If you we’re unable to make it, you can view the recording here: T1D Breakthroughs on the Horizon, Virtual Research Update
If you are interested in hearing more about clinical trials, please visit https://www.breakthrought1d.org/clinical-trials/
This session highlights exciting progress in T1D research, including the following key topics:
Cell Therapies
Learn why Sana Biotechnology’s gene-edited beta cells that are protected from the immune system (without the need for immunosuppressants) represent a promising breakthrough. We’ll also explore advancements from other research teams working towards cures for T1D.
Early Interventions
Momentum continues to build around ways to slow, or even stop, the progression of T1D in its early stages. In November of 2022, teplizumab (Tzield) became the first drug approved by the FDA to delay onset of T1D. We will cover the importance of T1D screening, an overview of the stages, and how Tzield and other drugs in clinical trials are seeking to stop T1D in its tracks.
Technology Advancements
While we wait for other cures, technology for managing T1D continues to improve! We will take a look at upcoming developments in CGMs and pumps, including longer-lasting devices, improved ease of use, and more choices for people living with T1D.